CT7001

PreclinicalSmall molecule

CCarrick Therapeutics Limited

CT7001 is one of 6 small molecule programs targeting Advanced Solid Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid MalignanciesCompleted

Advanced Solid MalignanciesPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Advanced Solid Malignancies

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Faslodex

FFresenius Kabi Oncology Ltd.

Preclinical

2 3

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 4

Trastuzumab Deruxtecan

AstraZeneca

Preclinical

1 5

AZD9574

AstraZeneca

Preclinical

1 6

CT7001

CCarrick Therapeutics Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

Completed·CCarrick Therapeutics Limited·Preclinical·NCT03363893·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CT7001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT7001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT7001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Carrick Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCarrick Therapeutics Limited

CT7001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News